Stage II Invasive Ductal Carcinoma: Margaret's Survivor Story

Patient Info: Margaret, Female | Stage II

Biomarkers: Onco-typing score 18; hormone-responsive tumor described; exact receptor status not reported

As of June 2026, Margaret’s story described completed surgery, chemotherapy, radiation, and later reconstruction for Stage II IDC/DCIS breast cancer, with survivorship focused on recovery, neuropathy, and integrative support rather than an explicit NED claim.

The Patient StoryRead more →

Stage II HR-Positive Breast Cancer: Bethany's Patient Story

Patient Info: Bethany W., Female, Under 40 | Stage II

Biomarkers: ER-positive; hormone-positive

As of June 2026, Bethany described care for late Stage II/early Stage III ER-positive breast cancer, beginning with AC chemotherapy and Taxol after scans showed no distant spread, with surgery, radiation, and hormone therapy planned as next phases.

The Patient StoryRead more →

Stage III Colorectal Cancer: Joanna's Survivor Story

Patient Info: Joanna, Female | Stage III

As of June 2026, Joanna’s story emphasized survivorship after Stage III rectal cancer, with major themes of delayed diagnosis, fertility preservation, radiation/chemotherapy planning, and the emotional recovery that followed treatment.

The Patient StoryRead more →

Stage III Triple-Negative Breast Cancer: Stephanie's Survivor Story

Patient Info: Stephanie, Female | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1 mutation

As of June 2026, Stephanie described being a 10-year survivor after Stage III BRCA1-positive triple-negative breast cancer, with remission shown after chemotherapy and no recurrence described.

The Patient StoryRead more →

Stage III Colorectal Cancer: Catherine's Patient Story

Patient Info: Catherine, Female | Stage III

Catherine had a complete pathological response after chemoradiation and surgery for Stage III rectal cancer, then continued adjuvant Xeloda/oxaliplatin while waiting for post-treatment scans before accepting an NED label.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Doreen's Patient Story

Patient Info: Doreen, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Doreen had completed TCHP chemotherapy with a complete response before surgery and had undergone lumpectomy and radiation for Stage IIA triple-positive breast cancer.

The Patient StoryRead more →

Stage III Lung Cancer: Peter's Survivor Story

Patient Info: Peter, Male, 70+ | Stage III

As of May 2026, Peter said his left-lung mass had gone after radiotherapy with chemotherapy and that he had returned to normal activities.

YouTube (AR search)Read more →

Stage IV Colorectal Cancer: Ken's Patient Story

Patient Info: Ken, Male, 50s | Stage IV

Metastatic Site: Liver

As of May 2026, Ken was more than 3 years into Stage IV colorectal cancer. He was not cancer-free or NED, but described the disease as minimal and manageable with surveillance, maintenance chemotherapy/targeted therapy, and occasional ablation.

The Patient StoryRead more →

Stage III Colorectal Cancer: Ben's Patient Story

Patient Info: Ben Schultz, Under 40 | Stage III

Ben achieved a complete response and, 6 years later, remained on watch-and-wait surveillance with regular scans.

Fight Colorectal CancerRead more →

Stage IV Non-Small Cell Lung Cancer: Jill's Patient Story

Patient Info: Jill, Female, 50s | Stage IV

Biomarkers: Driver mutation identified; specific mutation not stated

Metastatic Site: pleura

As of May 2026, Jill had lived 17 years with NSCLC, later experienced pleural metastases/progression, and remained on biomarker-guided targeted therapy with chemotherapy added.

The Patient StoryRead more →

Stage IV Colorectal Cancer: Carrie's Patient Story

Patient Info: Carrie, Female | Stage IV

Metastatic Site: ovaries; uterus; retroperitoneal/behind-kidney tumor

As of May 2026, Carrie had recurrent Stage IV signet ring cell colon cancer after a prior no-evidence-of-disease period and was receiving more aggressive chemotherapy plus radiation after surgery for a tumor behind the kidney.

The Patient StoryRead more →

Stage IV EGFR-mutated lung cancer responds after targeted therapy intolerance

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; PIK3CA E545K mutation; acquired ROS1 rearrangement

Metastatic Site: pleura|pericardium|bone|lungs

Chemotherapy produced a partial response that remained sustained for 7 months at the latest follow-up.

PubMed CentralRead more →

Growing teratoma syndrome after ovarian germ cell tumor treatment: Case 1

Patient Info: Anonymized, Female, Under 40

Biomarkers: AFP and beta-hCG elevated

Five months after completing therapy, her tumor markers were normal and there was no evidence of disease.

PubMed CentralRead more →

Growing teratoma syndrome after ovarian germ cell tumor treatment: Case 2

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: AFP and beta-hCG elevated

After surgery and completion of chemotherapy in January 2025, she was without disease and her tumor markers were normal.

PubMed CentralRead more →

Stage II KRAS Lung Adenocarcinoma: Roy's Survivor Story

Patient Info: Roy, Male, 50s | Stage II

Biomarkers: KRAS

As of May 2026, Roy described being cancer-free/in remission, back to flying professionally, and strong enough to complete his 5th marathon at the Boston Marathon.

The Patient StoryRead more →

Stage IV rectal mucinous adenocarcinoma with pancreatic metastasis: response to chemotherapy and staged surgery

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: CA 19-9 93.4 U/mL; CEA 3.4 ng/mL; pancreatic lesion biopsy consistent with colorectal origin

Metastatic Site: pancreas

As of May 2026, he had good clinical progress during 5 months of follow-up after staged treatment, including chemoradiation, FOLFOX, abdominoperineal resection, FOLFIRINOX, and Whipple resection of the pancreatic metastasis.

PubMed CentralRead more →

Lung cancer treated with tislelizumab: rare fluid buildup around the lung as a side effect

Patient Info: Anonymized, Male, 60s

After treatment of the bronchial-stump recurrence, the tumor remained stable. The delayed pleural effusion resolved within 10 days of methylprednisolone, and tumor stability continued for the next 15 months.

PubMed CentralRead more →

Metastatic triple-negative breast cancer with orbital and bone metastases responding to nab-paclitaxel plus everolimus

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Primary breast cancer was ER-low, PR/HER2 negative. Orbital metastasis was triple-negative with AKT1 exon 4 mutation.

Metastatic Site: right orbit/orbital mass; bone

At 6-month follow-up, systemic disease was stable, ocular symptoms had significantly improved, orbital metastases were stable on MRI, and the response was described as RECIST partial response/progression-free interval while treatment continued.

PubMed CentralRead more →

Rectal cancer that spread through the lungs: complete remission after BRAF-targeted therapy

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: BRAF mutation; HER2-negative; microsatellite stable; no detectable KRAS or NRAS mutations

Metastatic Site: lungs (pulmonary lymphangitic carcinomatosis);…

After progression with recurrent lung metastases and a new pericardial effusion, she chose hospice care and died in February 2025, 19 months after diagnosis.

PubMed CentralRead more →

Breast cancer treatment during pregnancy followed by postpartum targeted therapy

Patient Info: Anonymized, Female, Under 40 | Stage IV

She achieved a near-complete response after 4 cycles of docetaxel and then continued systemic treatment after delivery.

PubMed CentralRead more →

Stage II Ovarian Squamous Cell Carcinoma: Caitlin's Survivor Story

Patient Info: Caitlin Koehler, female, Under 40 | Stage II

Biomarkers: PD-L1: high expression

After surgery for recurrence, Caitlin remained on maintenance therapy and her follow-up scans showed no evidence of disease.

MD AndersonRead more →

Stage IIB triple-negative metaplastic breast cancer with early metastatic recurrence: durable response to pembrolizumab-based therapy

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Triple-negative metaplastic breast cancer with PD-L1 CPS 83.2, BRCA1/2 negative

Metastatic Site: lung, sternum

As of May 2026, she had more than 30 months of disease control after pembrolizumab-based therapy for early recurrent metastatic metaplastic breast cancer, with only mild residual sternal uptake and no disease progression.

PubMed CentralRead more →

My Metastatic Breast Cancer Spread To My BRAIN!

Patient Info: Anonymized, Female, 40s | Stage IV

Metastatic Site: brain

As of May 2026, the patient was living with metastatic breast cancer involving the brain, receiving 2 brain-directed chemotherapy infusions every 3 weeks, and describing the disease as chronic rather than a death sentence.

YouTube — The Patient StoryRead more →

Stage IV ALK Lung Cancer: Jake's Patient Story

Patient Info: Jake, Male, Under 40 | Stage IV

Biomarkers: ALK-positive mutation

Metastatic Site: brain; lung; ankle bone

As of May 2026, Jake was 28 and had lived more than 13 years with Stage IV ALK-positive lung cancer, with ongoing treatment history including targeted therapy, surgeries, radiation, clinical-trial therapy, and recent chemotherapy.

The Patient StoryRead more →